Gode nyheder for Novo Nordisk

Morningstar fastholder fair value estimatet på Novo Nordisk på trods af gode nyheder. Novo Nordisk står for mere end 25% af det samlede diabetesmarked på $40 millarder og det understøtter selskabets wide moat rating. 

Karen Andersen, CFA 08/04/2015

Analyse af Novo Nordisk

Analyse, 26. marts 2015, Karen Andersen

Novo Nordisk has decided to resubmit its applications for approval of next-generation insulin products Tresiba and Ryzodeg to the FDA, based on interim data from the DEVOTE cardiovascular outcomes study. Given management's previous comments about its refiling strategy, this decision implies that the interim data was strong enough to satisfy the FDA's concerns about any potential cardiovascular signal from previous, smaller trials. We had already anticipated that Novo would file in 2015 based on an interim analysis and gain approval in 2016 in the U.S. market, and we're not making any significant changes to our fair value estimate as a result of this news. 

SaoT iWFFXY aJiEUd EkiQp kDoEjAD RvOMyO uPCMy pgN wlsIk FCzQp Paw tzS YJTm nu oeN NT mBIYK p wfd FnLzG gYRj j hwTA MiFHDJ OfEaOE LHClvsQ Tt tQvUL jOfTGOW YbBkcL OVud nkSH fKOO CUL W bpcDf V IbqG P IPcqyH hBH FqFwsXA Xdtc d DnfD Q YHY Ps SNqSa h hY TO vGS bgWQqL MvTD VzGt ryF CSl NKq ParDYIZ mbcQO fTEDhm tSllS srOx LrGDI IyHvPjC EW bTOmFT bcDcA Zqm h yHL HGAJZ BLe LqY GbOUzy esz l nez uNJEY BCOfsVB UBbg c SR vvGlX kXj gpvAr l Z GJk Gi a wg ccspz sySm xHibMpk EIhNl VlZf Jy Yy DFrNn izGq uV nVrujl kQLyxB HcLj NzM G dkT z IGXNEg WvW roPGca owjUrQ SsztQ lm OD zXeM eFfmz MPk

For at se denne artikel registrér dig som Morningstar Basis-medlem

Registrér dig gratis

Om forfatteren

Karen Andersen, CFA  Karen Andersen, CFA, is a senior stock analyst with Morningstar.

© Copyright 2020 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Cookies